Which GLP-1 providers have FDA warning letters? 16 companies, 9 of them programs we rank
This tracker contains 16 sourced FDA warning-letter records involving compounded GLP-1 marketing or sales, and 9 are programs we rank ourselves: Sprout Health, Hers, Eden Health GLP-1, Maximus, Direct Meds GLP-1, SkinnyRx, MEDVi, Belle, Strut Health. Every row links to the letter on fda.gov by its reference number.
The FDA has issued far more than are listed here; we publish only the ones we have located and verified.
Across the sourced letters, FDA cited issues including:
- Marketing that implied compounded products were the same as, or FDA-reviewed like, approved brands
- Labels that obscured which entity compounded the prescription
- Unlawful online sales of unapproved or misbranded products in some letters
Not every letter makes every allegation, and a marketing or labeling citation is not by itself a finding that medication was unsafe.
Checking a Victory Medical Center Pharmacy vial? See the semaglutide and tirzepatide recall label check for the exact products and lots in FDA event 100168.
Companies with FDA warning letters
Every row below links to the FDA warning letter itself, by its MARCS-CMS reference number.
This list is not exhaustive. The FDA has issued far more, and we only publish letters we have located and linked.
Rows marked we rank this provider are companies that appear in our own rankings, including ones we earn affiliate commission from.
| Company | Warning date | Reason | Source |
|---|---|---|---|
| Sprout Healthwe rank this provider | 2025-09-09 | FDA warning letter to Sprout Health Partners LLC dba Sprout Health (MARCS-CMS 715879) found misleading marketing on joinsprouthealth.com that implied its compounded semaglutide and tirzepatide were the same as FDA-approved products. The letter concerns misbranding through those claims; it does not establish that a dispensed batch was unsafe. | FDA #715879 |
| Hims | 2025-09-09 | FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567), part of the September 9, 2025 wave against online sellers of compounded GLP-1s: 'same active ingredient as Ozempic and Wegovy'-class sameness claims on compounded semaglutide product pages, which the FDA holds imply an equivalence an unapproved compounded drug does not have. | FDA #716567 |
| Herswe rank this provider | 2025-09-09 | FDA warning letter to Hims & Hers Health, Inc. dba Hers (MARCS-CMS 716825), same September 9, 2025 wave and same conduct class as the Hims letter: sameness claims on compounded semaglutide product pages. | FDA #716825 |
| Zealthy | 2025-09-09 | FDA warning letter to FitRX, LLC dba Zealthy (MARCS-CMS 716501), September 9, 2025 wave against online sellers of compounded GLP-1s: after reviewing getzealthy.com in August 2025, FDA found the claims about compounded semaglutide products false or misleading under FDCA sections 502(a) and 502(bb). | FDA #716501 |
| MyStart Health | 2025-09-09 | FDA warning letter to Matthew Stern, CEO, MyStart Health LLC (MARCS-CMS 714755), September 9, 2025 wave: after reviewing mystarthealth.com in August 2025, FDA found the claims about the site's compounded semaglutide false or misleading under FDCA sections 502(a) and 502(bb). | FDA #714755 |
| Eden Health GLP-1we rank this provider | 2026-06-08 | Part of the FDA's June 8, 2026 action against telehealth companies marketing compounded GLP-1 drugs: false or misleading claims rendering the products misbranded. | FDA #728279 |
| Maximuswe rank this provider | 2026-06-08 | FDA review of the Maximus website in May 2026 found it offering compounded semaglutide and tirzepatide products with claims the agency deemed false or misleading, rendering them misbranded. | FDA #730095 |
| Direct Meds GLP-1we rank this provider | 2025-09-09 | FDA warning letter to directmeds.com, Inc. dba DirectMeds (MARCS-CMS 716822), September 9, 2025: after reviewing directmeds.com in August 2025, FDA found that claims such as compounded semaglutide containing the same active ingredient as branded semaglutide were false or misleading under FDCA sections 502(a) and 502(bb). The letter concerns misbranding through those claims; it does not establish that a dispensed batch was unsafe. | FDA #716822 |
| SkinnyRxwe rank this provider | 2026-02-20 | Misbranding under FDCA 502(a) and 502(bb): compounded semaglutide and tirzepatide shown on skinnyrx.com carried labels identifying SkinnyRx, implying SkinnyRx compounded the drugs when it does not, alongside false or misleading website claims. | FDA #717989 |
| MEDViwe rank this provider | 2026-02-20 | Misbranding under FDCA 502(a) and 502(bb): MEDVi-branded product labels implied MEDVi compounded the drugs when it did not, and website claims comparing compounded semaglutide and tirzepatide with FDA-approved brands implied equivalence or FDA evaluation the compounded products do not have. | FDA #721455 |
| Bellewe rank this provider | 2026-02-20 | Misbranding under FDCA 502(a) and 502(bb): compounded semaglutide and tirzepatide pictured on joinbelle.com carried a "Belle" label, suggesting Belle was the compounder when it was not. FDA reviewed the site in December 2025. | FDA #721795 |
| FITISH | 2026-06-08 | False or misleading claims rendering compounded GLP-1 products misbranded, in the FDA's June 8, 2026 telehealth action. | FDA #728280 |
| Lovely Meds | 2025-09-09 | FDA review of the website in August 2025 found compounded semaglutide and tirzepatide offered with claims including 'Same active ingredient as Wegovy and Ozempic' and 'Same active ingredient as Zepbound & Mounjaro', which imply the compounded products are the same as the FDA-approved drugs when they are not. | FDA #716829 |
| GLP-1 Solution | 2025-09-09 | Unlawful sale of unapproved and misbranded drugs to United States consumers over the internet. | FDA #715883 |
| Vitals RX | 2025-09-09 | Unlawful sale of unapproved and misbranded drugs to United States consumers over the internet. | FDA #715868 |
| Strut Healthwe rank this provider | 2026-02-20 | Misbranding: compounded semaglutide/tirzepatide product labels displayed 'Strut' branding implying Strut itself was the compounder (it is not), and website marketing claims implied the compounded products were FDA-evaluated for safety and effectiveness. | FDA #721448 |
Want records without a sourced warning letter in this tracker? See the public-record list below, or search any tracked company in our Warning & Transparency Checker.
Absence from the tracker does not establish safety or compliance. For the short version, see which records warrant extra review and how to evaluate an online pharmacy.
When the letters were issued
Programs with no sourced FDA warning letter here
These providers in our partner comparison do not have a sourced FDA warning letter in our current dataset.
That is a limited public-record observation, not confirmation of safety, pharmacy licensing, current compliance, or operational legitimacy.
Each name links to its full review; see the underlying fields in our Warning & Transparency Checker.
Is my Victory Medical Center Pharmacy semaglutide or tirzepatide lot recalled?
FDA event 100168 includes the 11 semaglutide and tirzepatide combination product records below from Victory Medical Center Pharmacy in Austin, Texas. The listed reason is lack of processing controls. Match the pharmacy, full medicine combination, concentration, vial size and lot on your label. A medicine name or telehealth program alone cannot establish whether your vial matches.
| Medicine and concentration | Multi-dose vial | Lot and FDA-listed expiry | FDA record |
|---|---|---|---|
| Semaglutide/L-carnitine2.5/25 mg/mL | 1 mL |
| D-0139-2027 |
| Semaglutide/L-carnitine5/50 mg/mL | 1 mL |
| D-0140-2027 |
| Semaglutide/L-carnitine5/50 mg/mL | 3 mL |
| D-0141-2027 |
| Tirzepatide/B625/10 mg/mL | 1 mL |
| D-0147-2027 |
| Tirzepatide/B625/10 mg/mL | 8 mL |
| D-0148-2027 |
| Tirzepatide/L-carnitine25/50 mg/mL | 1 mL |
| D-0149-2027 |
| Tirzepatide/L-carnitine25/50 mg/mL | 3 mL |
| D-0150-2027 |
| Tirzepatide/L-carnitine25/50 mg/mL | 8 mL |
| D-0151-2027 |
| Tirzepatide/L-carnitine10/50 mg/mL | 1 mL |
| D-0152-2027 |
| Tirzepatide/L-carnitine30/100 mg/mL | 2 mL |
| D-0153-2027 |
| Tirzepatide/niacinamide20/2 mg/mL | 3 mL |
| D-0154-2027 |
Each expiry belongs to the lot beside it. These dates identify the recalled batches; they are not permission to use a recalled vial before its expiry. The concentrations describe the labels, not a recommended dose or a conversion between products.
The FDA event record lists a voluntary, firm-initiated Class II recall, with distribution in Colorado, Florida and Texas and initial notification by letter. It began and was classified . FDA listed it as ongoing when checked and says no press release was issued. The 2027 in the recall numbers is part of each identifier, not the year the recall began.
The full event contains other medicines; this table covers only its semaglutide and tirzepatide records. Lack of processing controls does not by itself establish that a particular vial was contaminated or caused harm. The record does not identify which telehealth programs, if any, supplied these lots. It does not recall every compounded GLP-1 medicine or an approved brand.
What should I do with a matching label?
Contact your dispensing pharmacy or prescriber with the label and complete lot code to obtain the company's recall instructions. The public event record does not give patient-specific, return or replacement instructions. Follow the company's instructions and ask your pharmacist or doctor about your medicine, as FDA's consumer recall guidance explains. This label check cannot decide whether you should stop, continue or change a dose. For broader approval and quality questions, read our compounded GLP-1 safety guide.
Is my Houston Rx tirzepatide/niacinamide lot recalled?
FDA recall D-0040-2027 covers Houston Rx LLC's tirzepatide/niacinamide injection at 20 mg/2 mg per mL in a 2 mL vial, lot TZN-080326-20/2-2. The listed reason is lack of assurance of sterility. Match the medicine, pharmacy, concentration and complete lot on your label; a telehealth program name alone cannot establish a match.
| Label detail | FDA-listed value |
|---|---|
| Pharmacy | Houston Rx LLC |
| Medicine and concentration | Tirzepatide/niacinamide, 20 mg/2 mg per mL |
| Vial size | 2 mL |
| Complete lot code | TZN-080326-20/2-2 |
| Beyond-use date |
The slash is part of a single lot code. The beyond-use date identifies the batch; it is not permission to use a recalled vial until that date.
The FDA product record lists 64 vials, nationwide US distribution and a Class II classification. The recall began September 25, was classified October 13 and appears in the October 21, 2026 weekly report. FDA listed it as ongoing when checked October 23. The 2027 in its recall number is part of the identifier, not the year it began. The record says no press release was issued.
This record does not identify which telehealth programs, if any, supplied the lot. Lack of assurance of sterility does not itself establish that a particular vial was contaminated. The same event, 99990, has a separate sermorelin product record, D-0041-2027; its product and lot must not be substituted for this tirzepatide/niacinamide record.
What should I do with a matching label?
Contact your dispensing pharmacy or prescriber with the label and complete lot code to obtain the company's recall instructions. The public record does not give product-specific patient, return or replacement instructions. Follow the recalling company's instructions and ask your pharmacist or doctor about your medicine, as FDA's consumer recall guidance explains. This label check cannot decide whether you should stop, continue or change a dose.
For broader approval and product-quality questions, read our compounded GLP-1 safety guide.
Is my Apothecary tirzepatide lot recalled?
FDA recall D-0036-2027 covers Apothecary Pharma's tirzepatide injection at 18 mg/mL in a 4 mL multi-dose vial, NDC 85091-001-18. The FDA lists the reason as lack of assurance of sterility. Check the medicine, pharmacy and lot number on your label against the record below. A telehealth program name alone cannot establish a match.
The record lists 22 vials, nationwide US distribution and a Class II classification. It was initiated September 24, classified October 8 and reported October 14, 2026. FDA still listed it as ongoing when checked on October 20. The 2027 in the recall number is part of the identifier; the recall began in 2026.
Source: FDA product record D-0036-2027, event 99952. It says no press release was issued. Lack of assurance of sterility does not, by itself, establish that a particular vial was contaminated. The record does not identify which telehealth programs, if any, supplied these lots.
| Lot on the pharmacy label | FDA-listed beyond-use date |
|---|---|
AP-202622 | |
AP-202623 | |
AP-202624 | |
AP-202625 | |
AP-202627 | |
AP-202628 | |
AP-202629 | |
AP-202630 | |
AP-202631 | |
AP-202632 | |
AP-202633 | |
AP-202634 | |
AP-202635 | |
AP-202636 | |
AP-202637 | |
AP-202638 | |
AP-202639 | |
AP-202640 | |
AP-202641 | |
AP-202642 | |
AP-202643 | |
AP-202644 |
These dates identify the listed batches; they are not permission to use a recalled vial until that date. FDA's separate NAD+ record in the same event is D-0037-2027. Its lot list must not be substituted for this tirzepatide list.
What should I do with a matching label?
Contact your dispensing pharmacy or prescriber with the label and lot number to obtain the company's recall instructions. This public record does not give product-specific patient, return or replacement instructions. Follow the recalling company's instructions and ask your pharmacist or doctor about your medicine, as FDA's consumer recall guidance explains. The table cannot decide whether you should stop, continue or change a dose.
For the broader product-quality and approval questions, read our compounded GLP-1 safety guide.
Semaglutide recalls in the compounding supply chain
A warning letter is about what a company said. A recall is about what shipped.
These are separate FDA channels with different firms in them, and none of the 4 firms in the compounding rows below is a program we rank, so no provider on this site is named in these records.
That cuts both ways: the compounder or the active-ingredient maker behind a telehealth brand is usually not disclosed to the patient, so a shopper generally cannot tell from the website whether their vial came through one of these firms.
What the 16 compounding-chain records do show is where the failures cluster, and as of the records reported 2026-08-19 that is no longer mainly sterility. 11 of the 16 were recalled for particulate matter, something physically in the vial, against 3 for sterility assurance and the rest for process and endotoxin validation at the raw-ingredient step.
All are Class II. The branded row is included for contrast, not for balance.
Every row is transcribed from the openFDA drug enforcement API most recently 2026-08-26, each row either by its FDA recall number or, for the Apollo Care cluster, by a report-date range query that returned the eleven records together.
The newest record here was reported 2026-08-19.
openFDA's enforcement index publishes on its own lag, so a recall more recent than that may not be indexed yet, and its absence here is not evidence it did not happen.
Every row carries the quantity, initiation date and distribution pattern openFDA reports for it; where a field reads N/A, that is what the record itself contains.
Status is FDA's own: Ongoing means the recall is not yet recorded as completed, so product may still be in the channel.
Class II means FDA judged that exposure may cause temporary or medically reversible harm, with a remote probability of serious harm.
Compounded semaglutide is not an FDA-approved product in any case, whatever its recall history.
| Recalling firm | Product | Reason | Initiated | Status | Record |
|---|---|---|---|---|---|
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-495-0556,918 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0747-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202 NDC 71170-811-0223,029 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0748-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202 NDC 71170-821-0137,546 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0749-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-812-039,762 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0750-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-822-0224,608 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0751-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-810-014,748 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0752-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-711-02250 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0753-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202.NDC 71170-712-03250 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0754-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-721-01250 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0755-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-722-02500 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0756-2026 |
| Apollo Care, LLCColumbia, MO · compounding pharmacy | SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-724-04.4,250 vials. recalled | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type materialClass II · distributed Nationwide within the U.S | 2026-07-29reported 2026-08-19 | Ongoingnot yet completed | D-0757-2026 |
| PAYLESS COMPOUNDERS, LLCBeaverton, OR · compounding pharmacy | Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR91 vials recalled | Lack of Assurance of SterilityClass II · distributed OR | 2026-03-06reported 2026-04-22 | Ongoingnot yet completed | D-0471-2026 |
| New Life Pharma LLCNorthvale, NJ · repackager / relabeler | Semaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, NDC 84223-001-07820 vials recalled | Lack of Assurance of SterilityClass II · distributed OH | 2026-02-26reported 2026-03-11 | Ongoingnot yet completed | D-0392-2026 |
| New Life Pharma LLCNorthvale, NJ · repackager / relabeler | Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, NDC 84223-001-062 vials recalled | Lack of Assurance of SterilityClass II · distributed OH | 2026-02-26reported 2026-03-11 | Ongoingnot yet completed | D-0393-2026 |
| Harbin Jixianglong Biotech Co., Ltd.Harbin, China · active-ingredient maker | Semaglutide, For Rx compounding use only, packaged in 1g, 5g, 10g, 25g and 50g (NDC 84385-106-01 through 84385-106-04) | CGMP Deviations. This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distributionClass II · distributed Nationwide within the United States | 2026-02-13reported 2026-03-11 | Ongoingnot yet completed | D-0379-2026 |
| Harbin Jixianglong Biotech Co., Ltd.Harbin, China · active-ingredient maker | Semaglutide, For Rx compounding use only, packaged in 1g, 5g, 10g, 25g, 50g and 100g (NDC 84385-106-01 through 84385-106-05) | CGMP Deviations. This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distributionClass II · distributed Nationwide within the United States | 2026-02-13reported 2026-03-11 | Ongoingnot yet completed | D-0380-2026 |
| Novo Nordisk Inc.Plainsboro, NJ · FDA-approved brand | Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, NDC 0169-4501-14 | Presence of Particulate Matter: Hair was found in a prefilled syringeClass II · distributed Nationwide within the United States. | 2025-12-19reported 2026-01-07 | Ongoingnot yet completed | D-0245-2026 |
Shopping compounded programs on price?
Our cheapest GLP-1 programs breakdown and brand vs compounded comparison both cover what you are trading away for the lower price.
Ask any provider which 503A or 503B pharmacy fills your prescription, and check that pharmacy against the FDA drug recall archive.
This is public-record reporting, not medical advice; talk to your prescriber before changing or stopping any medication.
Search any tracked company
Search our database of 39 tracked companies
Open Warning & Transparency CheckerHow to read a warning letter in this tracker
Each letter must be read for its own allegations. The sourced letters here fall into distinct categories, and no letter contains every one:
- Post-shortage compounding conditions. Ending enforcement discretion for shortage-based copies did not create a universal ban; each preparation must satisfy the applicable 503A or 503B and state-law conditions.
- Semaglutide salt forms. FDA says it is not aware of a lawful basis for using semaglutide sodium or acetate in compounding under the cited statutory conditions.
- Misleading brand comparisons. Several letters address claims that compounded products were approved, generic, identical or clinically equivalent to Wegovy, Ozempic, Zepbound or Mounjaro.
- Labeling, manufacturing or record issues. Letter-specific; never infer them from a marketing-only citation.
Three things the record does not say on its own.
A letter can name a marketer or telehealth provider even when another entity compounded the medication.
Semaglutide and tirzepatide claims both appear, so read the product and conduct cited rather than generalising across a company or a drug class.
And a warning letter is not a final adjudication; a later close-out record can change the current context materially.
FDA separately announced 30 telehealth marketing letters on March 3, 2026, which is broader than the individually linked rows here; this tracker is curated and not exhaustive, and publishes no cumulative national total for that reason.
If you are on a compounded GLP-1 today, four questions for your provider
- Which pharmacy fills my prescription? The answer should be a specific 503A or 503B pharmacy name, not "our network" or "our partner".
- Is that pharmacy on the FDA warning-letter list? Check the FDA database or the safety checker.
- What patient-specific rationale and legal pathway does the prescriber document? It should address the actual formulation and the applicable 503A or 503B conditions, not a generic claim that all compounded products are legal.
- What ingredient and concentration are on the label? Confirm the formulation, mg/mL concentration, vial size and syringe units with the dispensing pharmacist; never infer them from a brand dose.
If a provider cannot answer these, pause and ask the prescriber or pharmacist for the records before paying or dosing.
The safety checker summarises selected public records; it does not maintain a "verified compliant" list or certify any provider as safe.